PubMed Health⌕ Search

Biomedical subjects

N Kostova

Publications and source records attributed to N Kostova.

10 recordsLinked to original sources
PubMed1989

[Chronopharmacokinetics of the preparation biomet400 in patients with duodenal ulcer].

Biomet400 is a selective H2-blocker produced by the firm "Pharmacia" of the Bulgarian Medical Academy. 11 patients were treated with the drug in a dose of 400 mg taken orally in the morning or in the evening. The pharmacokinetic analysis revealed a slower resorption of cimetidine in the patients who had taken the drug in the evening (Tmax = 2 h, resp. 1.67 h) and a lowered Cmax (1.96 micrograms/ml, resp. 2.79 micrograms/ml) in comparison with the patients who had taken the drug in the morning. In the patients who had taken the drug in the evening the apparent volume of distribution is statistically significantly higher (242 l, resp. 124 l by the morning administration) and a tendency toward a slower elimination than by the morning administration is found (t1/2 = 4.41 h, resp. 3.89 h). In the patients who had taken the drug in the morning the elimination is mainly by renal excretion (Clr = 405 ml/min, resp. 3.29 ml/min for the evening administration) while in the patients with evening administration the nonrenal clearance prevails (Clnr = 534 ml/min, resp. 339 ml/min). The results indicate the presence of chronopharmacokinetic differences in the cimetidine action and they can explain the better chronotherapeutic results of the treatment with biomet400 administered in the evening.

Administration, Oral↗
PubMed1986

Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone.

The effectiveness of the nonsteroidal anti-inflammatory agent nabumetone is related to the formation of an active metabolite: 6-methoxy-2-naphthylacetic acid. The plasma concentrations of nabumetone and its active metabolite, after administration of 1,000 mg single dose p.o., are followed at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 30 and 48 h in 6 patients with laboratory evidence for functional liver insufficiency caused by liver cirrhosis, confirmed by biopsy. In the patients with liver insufficiency the mean values of Cmax and AUC0-24 h for 6-methoxy-2-naphthylacetic acid were 26.75 +/- 8.45 mg/l and 623.64 +/- 161.8 mg X h/l respectively. They did not differ significantly from the values observed in healthy volunteers [v. Schrader et al. 1983]. The Tmax-value was prolonged to 8 h, compared to 4 h Tmax-value of the volunteers. There is a tendency towards a reduced bioavailability of 6-methoxy-2-naphthylacetic acid after nabumetone administration in patients with a more severely expressed pathologic impairment, compared to patients with slight morphologic changes of the liver parenchyma.

Aged↗
PubMed1985

[Microbiological research on processed cheese].

Microbiologic studies were carried out with a total of 136 batches of 8 assortments of softened cheese to establish the amount and composition of the microbial content of this product. It was found that the total count of mesophilic organisms of 72.8 per cent of the investigated batches reached up to 200 000/g. The content of hygiene-indicative organisms (coliforms and enterococci) was limited: 97 per cent of batches had a coli titer of 1 and over 1. The content of enterococci in 54.4 per cent of the investigated was below 100/g, and in 4.4 per cent it was over 100 000/g. No Salmonella bacteria and plasmacoagulase positive staphylococci in 25, resp., 10 g of the product were found. Contamination with sporeforming aerobic and anaerobic organisms in 72.1, resp., 91.9 per cent reached up to 1000, resp., 100 per gram of the product. The amount of proteolytic bacteria in 61.8 per cent of the batches was up to 1000/g, and in 8 per cent only--up to 100 000/g. The content of yeasts and moulds in 58.8, resp. 83.1 per cent of the batches was below 100/g.

Bacteria↗
PubMed1982

[Clinical observations on the therapeutic activity of the preparation mendiaxon in diseases of the biliary tract].

The immediate effect of 400 mg mendiaxon was studied in 8 patients with various hepatobiliary diseases. The drug was administered via a duodenal tube in a duodenal drainage tubing according to a minute schedule during the phase of pure bile C secretion. An increased volume was found in all cases. The maximum choleresis exceeds the basal one from 3 to 8 times. The rate of bile flow, in the majority of the patients, was between 2 and 3.3. ml/min. The treatment was carried out on 25 patients in the course of 10 days with a daily dose of 1200 mg (400 mg three times). A good pain-killing effect was obtained. Adverse effects and allergic reactions were not observed. The results from our studies provided grounds to recommend mendiaxon use in the clinical practice.

Adult↗
PubMed1976

[Biochemical and technological characteristics of the milk from Black-and White Dutch].

Studied were the composition and the technologic properties of the milk of Dutch Black pied cattle under this country's conditions. Milk samples were taken for analysis once in a month on a cow farm founded in 1964 with a total of 67 impregnated heifers and having at the time of investigation 88 cows, twelve of them remaining from the initial animals imported from Holland and the others being the offspring of the herd. It was established that the annual milk yield per forage cow, amounting to 44881 has the following index values; dry matter--12.63 +/- 0.48 per cent; butterfat per cent--4.07 +/- 0.2%; total protein--3.37 +/- 0.16 per cent; casein--2.56 +/- 0.16; slids-nonfat--8.54 +/- 0.24 per cent; calcium--0.126 +/- 0.002 per cent; phosphorus--0.079 +/- 0.003 per cent. The technologic properties of milk proved unsatisfactory: coagulation capacity--359 s; rheologic value--112.93 X 1.10(-5) V/cm3; and technologic coeficient--1.32. The data on the composition and the technologic properties of Dutch Black-pied cow's milk showed, on the whole, that most profitable is its processing into butter as against processing into cheese in which case the yields would be unsatisfactory.

Animals↗